Drug Inhibits Epigenetic Enzyme To Treat Leukemia and Neuropsychiatric Disorders with Carlos Buesa Oryzon Genomics

Carlos Buesa, CEO of Oryzon Genomics, specializes in developing precision medicine based on epigenetics, the regulatory mechanisms that control gene expression without altering the DNA. A key target is the LSD1 enzyme which regulates cell differentiation and is a factor in acute myeloid leukemia and CNS disorders. LSD1 inhibition addresses a fundamental insight that the same dysregulated epigenetic genes implicated in leukemia also drive various neruopsychiatric and genetic syndromes suggesting a unified mechanistic understanding of diverse diseases.  Carlos explains, "Epigenetics has been the  i specialization of Oryzon for many years already. We were, I mean, founded back in 2000, but in the last 12 years, we started to develop precision medicines for cancer, broad disorders, and CNS diseases based on epigenetics. And epigenetics, as the name suggests, is something that is above genetics. It's another supplementary level of control that our cells or our organisms have to basically adapt to the changing world. So, epigenetics is a very complex system comprised of many, many different proteins which control which genes are switched on or off without changing the underlying DNA sequence. What we have seen over the last few years is that in disease, those control mechanisms can become dysregulated. And importantly, many epigenetic changes are potentially reversible. So, our strategy here is to develop drugs that act on particular enzymes, epigenetic enzymes, controlling those changes and resetting our normal gene programs."   "A beautiful example of that is leukemia, where there is an extraordinarily complex genetic background, and different epigenetic enzymes offer the capacity to modulate and restore the physiological status to delay the disease, basically to modify the basis of oncological progression. But it's not the only one. We know that epigenetics is working on many other diseases in metabolism, in GI, and some others, but we are also focused on neuropsychiatric disorders. So, these are the two focuses of the company using epigenetics." #OryzonGenomics #Epigenetics #Oncology #Hematology #Schizophrenia #AML #CNS #PrecisionMedicine #ClinicalTrials #HealthcareInnovation #Neuroscience #CNSdisorders #AcuteMyeloidLeukemia #SickleCellDisease oryzon.com Listen to the podcast here

Carlos Buesa, CEO of Oryzon Genomics, specializes in developing precision medicine based on epigenetics, the regulatory mechanisms that control gene expression without altering the DNA. A key target is the LSD1 enzyme which regulates cell differentiation and is a factor in acute myeloid leukemia and CNS disorders. LSD1 inhibition addresses a fundamental insight that the same dysregulated epigenetic genes implicated in leukemia also drive various neruopsychiatric and genetic syndromes suggesting a unified mechanistic understanding of diverse diseases.  Carlos explains, "Epigenetics has been the  i specialization of Oryzon for many years already. We were, I mean, founded back in 2000, but in the last 12 years, we started to develop precision medicines for cancer, broad disorders, and CNS diseases based on epigenetics. And epigenetics, as the name suggests, is something that is above genetics. It's another supplementary level of control that our cells or our organisms have to basically adapt to the changing world. So, epigenetics is a very complex system comprised of many, many different proteins which control which genes are switched on or off without changing the underlying DNA sequence. What we have seen over the last few years is that in disease, those control mechanisms can become dysregulated. And importantly, many epigenetic changes are potentially reversible. So, our strategy here is to develop drugs that act on particular enzymes, epigenetic enzymes, controlling those changes and resetting our normal gene programs."   "A beautiful example of that is leukemia, where there is an extraordinarily complex genetic background, and different epigenetic enzymes offer the capacity to modulate and restore the physiological status to delay the disease, basically to modify the basis of oncological progression. But it's not the only one. We know that epigenetics is working on many other diseases in metabolism, in GI, and some others, but we are also focused on neuropsychiatric disorders. So, these are the two focuses of the company using epigenetics." #OryzonGenomics #Epigenetics #Oncology #Hematology #Schizophrenia #AML #CNS #PrecisionMedicine #ClinicalTrials #HealthcareInnovation #Neuroscience #CNSdisorders #AcuteMyeloidLeukemia #SickleCellDisease oryzon.com Download the transcript here

Paul Romness, CEO, President, and Chair of OS Therapies, which is developing an immunotherapy to treat osteosarcoma, a rare bone cancer that stimulates the immune system to identify and eliminate cancer cells. The approach upregulates positive immune factors amd downregulates negative factors resulting in a dual biomarker response and better management of side effects. OS Therapies plans to expand its platform technology to other solid tumors with significant unmet needs, including breast,  esophageal, and colorectal cancer.    Paul explains, "What I think is important is that OS Therapies was started for unmet need, not just in the United States, but there are 20,000 patients a year that get osteosarcoma globally. And it's our responsibility to address patients globally. And it is interesting from a regulatory standpoint, as they start to coordinate with each other, that there are routes for us to get approval in the United States through MHRA, through the UK, and through the collaboration with the EU, with a system called Orbis. But we're also still very confident and very encouraged by the progress we've made with the FDA over the last few months."   "And for OS Therapies, we will pivot to other solid tumors. So our primary mission is osteosarcoma, but once we get approval, we'll pivot to other solid tumors that still have a lot of unmet medical need, like breast cancer. There are still 40,000, mostly women, dying each year of breast cancer, esophageal cancer, or colorectal cancer. So if we can encourage other companies to come into this space, we'll not only achieve our primary mission, but we'll also deliver for patients, which is our goal." #OSTherapies #Osteosarcoma #RareDisease #RareCancer #PediatricOncology #RareDiseaseOncology #SolidTumors #Immunotherapy #ListeriaCancerImmunotherapy #Biomarkers #Oncology #ClinicalTrials #HER2 #CancerResearch #ComparativeOncology#CanineOsteosarcoma ostherapies.com Listen to the podcast here

Paul Romness, CEO, President, and Chair of OS Therapies, which is developing an immunotherapy to treat osteosarcoma, a rare bone cancer that stimulates the immune system to identify and eliminate cancer cells. The approach upregulates positive immune factors amd downregulates negative factors resulting in a dual biomarker response and better management of side effects. OS Therapies plans to expand its platform technology to other solid tumors with significant unmet needs, including breast,  esophageal, and colorectal cancer.    Paul explains, "What I think is important is that OS Therapies was started for unmet need, not just in the United States, but there are 20,000 patients a year that get osteosarcoma globally. And it's our responsibility to address patients globally. And it is interesting from a regulatory standpoint, as they start to coordinate with each other, that there are routes for us to get approval in the United States through MHRA, through the UK, and through the collaboration with the EU, with a system called Orbis. But we're also still very confident and very encouraged by the progress we've made with the FDA over the last few months."   "And for OS Therapies, we will pivot to other solid tumors. So our primary mission is osteosarcoma, but once we get approval, we'll pivot to other solid tumors that still have a lot of unmet medical need, like breast cancer. There are still 40,000, mostly women, dying each year of breast cancer, esophageal cancer, or colorectal cancer. So if we can encourage other companies to come into this space, we'll not only achieve our primary mission, but we'll also deliver for patients, which is our goal." #OSTherapies #Osteosarcoma #RareDisease #RareCancer #PediatricOncology #RareDiseaseOncology #SolidTumors #Immunotherapy #ListeriaCancerImmunotherapy #Biomarkers #Oncology #ClinicalTrials #HER2 #CancerResearch #ComparativeOncology#CanineOsteosarcoma ostherapies.com Download the transcript here

Dejan Nenov is the Founder of Luventix, an AI-powered diagnostic platform that uses machine learning to analyze metabolic data from urine samples to detect multiple diseases and health conditions.  This approach, inspired by the ability of dogs to detect cancer through smell, enables a single non-invasive test to screen for conditions across oncology, neurology, immunology, and other areas at a fraction of the cost of genetic sequencing or blood tests.  The platform has applications in precision medicine, patient stratification for clinical trials, and population-level health screening.     Dejan explains, "The origin story is actually quite fun. One of my two co-founders and I were sitting around his dining table after a day of skiing and watching TV, and we saw dogs smelling urine and sitting down when the urine was from a cancer patient. And so we started thinking, can we reproduce this with technology? And we looked at it and said, "Well, what does the dog's nose do?" And we said, "Well, it's identifying the molecules in the volatiles of the sample, the urine. That looks suspiciously like gas chromatography."   "And then what happens? Well, the dog's brain determines whether the sample is positive or negative. And that's a classifier, a classic classification problem based on a dataset. So we roll back a year or so, and my co-founder Martin did a study to explore whether he could build models to do what the dogs did, but consistently in a mechanistically repeatable fashion."   "We demonstrated that, yes, indeed, based on creating a digital twin of the patient's organism using metabolic data from a urine sample, we're able to train models that can determine whether a disease or condition is present from a urine sample. In the most general case, that's sort of a patient stratification technology." #Luventix #DigitalHealth #PrecisionMedicine #HealthTech #AIinHealthcare #PatientEmpowerment #HealthInnovation #FutureOfHealthcare #DiagnosticInnovation #HealthTechStartup #ConnectedHealth#HealthcareInnovation #AIinHealthcare #Diagnostics #CancerDetection #MedicalAI #ClinicalTrials #Metabolomics #FutureOfMedicine luventix.com  Listen to the podcast here

Dejan Nenov is the Founder of Luventix, an AI-powered diagnostic platform that uses machine learning to analyze metabolic data from urine samples to detect multiple diseases and health conditions.  This approach, inspired by the ability of dogs to detect cancer through smell, enables a single non-invasive test to screen for conditions across oncology, neurology, immunology, and other areas at a fraction of the cost of genetic sequencing or blood tests.  The platform has applications in precision medicine, patient stratification for clinical trials, and population-level health screening.     Dejan explains, "The origin story is actually quite fun. One of my two co-founders and I were sitting around his dining table after a day of skiing and watching TV, and we saw dogs smelling urine and sitting down when the urine was from a cancer patient. And so we started thinking, can we reproduce this with technology? And we looked at it and said, "Well, what does the dog's nose do?" And we said, "Well, it's identifying the molecules in the volatiles of the sample, the urine. That looks suspiciously like gas chromatography."   "And then what happens? Well, the dog's brain determines whether the sample is positive or negative. And that's a classifier, a classic classification problem based on a dataset. So we roll back a year or so, and my co-founder Martin did a study to explore whether he could build models to do what the dogs did, but consistently in a mechanistically repeatable fashion."   "We demonstrated that, yes, indeed, based on creating a digital twin of the patient's organism using metabolic data from a urine sample, we're able to train models that can determine whether a disease or condition is present from a urine sample. In the most general case, that's sort of a patient stratification technology." #Luventix #DigitalHealth #PrecisionMedicine #HealthTech #AIinHealthcare #PatientEmpowerment #HealthInnovation #FutureOfHealthcare #DiagnosticInnovation #HealthTechStartup #ConnectedHealth#HealthcareInnovation #AIinHealthcare #Diagnostics #CancerDetection #MedicalAI #ClinicalTrials #Metabolomics #FutureOfMedicine luventix.com Download the transcript here

Dr. Hansa Bhargava, Chief Clinical Strategy and Innovation Officer at Healio,  discusses the Healio survey of healthcare professionals to understand evolving attitudes toward AI in clinical practice.  While a significant number of clinicians are leaning into AI adoption, significant trust gaps persist regarding accuracy, data privacy and liability concerns. As AI capabilities advance rapidly, healthcare organizations face pressure to adopt these technologies while maintaining rigorous safeguards and establishing clear policies around shadow AI usage and preserving the human-in-the-loop approach. Hansa explains, "Our core mission is really to support and engage doctors and clinicians in the work that they do. To give you a broad viewpoint, there are about two million peer-reviewed publications a year, and doctors, nurses, and clinicians need to stay up to date to deliver the best quality care to patients. And that is sometimes impossible considering the number of hours that they're doing in the clinical setting. So our goal and our vision are to support them by giving them the information right away and sound bites that they can digest quickly and also get to quickly. Because of that vision and mission, we developed Healio AI to make it even faster and more available in a pure format and using good data sources so that they have the information they need for their patients."   "It's almost impossible for anyone to keep up with those changes. They're exponential, as you just said. And yes, that's definitely a concern, but the other concerns are just fundamental issues of accuracy of the AI delivering the right answers, whether it's frontier models or whether it's a model such as developed by Healio. And then also privacy of patients, data privacy, and also legalities in terms of who holds the bag if things go astray." #Healio #HealioAI #DigitalHealth #HealthcareAI #GenAI #MedicalTechnology #HealthcareProfessionals #CME #PointOfCare #MedicalInformation #HealthTech #PhysicianBurnout #ContinuingEducation #HealthcareInnovation #MedicalJournalism #AIinHealthcare Healio.com  Listen to the podcast here

Dr. Hansa Bhargava, Chief Clinical Strategy and Innovation Officer at Healio,  discusses the Healio survey of healthcare professionals to understand evolving attitudes toward AI in clinical practice.  While a significant number of clinicians are leaning into AI adoption, significant trust gaps persist regarding accuracy, data privacy and liability concerns. As AI capabilities advance rapidly, healthcare organizations face pressure to adopt these technologies while maintaining rigorous safeguards and establishing clear policies around shadow AI usage and preserving the human-in-the-loop approach. Hansa explains, "Our core mission is really to support and engage doctors and clinicians in the work that they do. To give you a broad viewpoint, there are about two million peer-reviewed publications a year, and doctors, nurses, and clinicians need to stay up to date to deliver the best quality care to patients. And that is sometimes impossible considering the number of hours that they're doing in the clinical setting. So our goal and our vision are to support them by giving them the information right away and sound bites that they can digest quickly and also get to quickly. Because of that vision and mission, we developed Healio AI to make it even faster and more available in a pure format and using good data sources so that they have the information they need for their patients."   "It's almost impossible for anyone to keep up with those changes. They're exponential, as you just said. And yes, that's definitely a concern, but the other concerns are just fundamental issues of accuracy of the AI delivering the right answers, whether it's frontier models or whether it's a model such as developed by Healio. And then also privacy of patients, data privacy, and also legalities in terms of who holds the bag if things go astray." #Healio #HealioAI #DigitalHealth #HealthcareAI #GenAI #MedicalTechnology #HealthcareProfessionals #CME #PointOfCare #MedicalInformation #HealthTech #PhysicianBurnout #ContinuingEducation #HealthcareInnovation #MedicalJournalism #AIinHealthcare Healio.com  Download the transcript here

Dr. Carl Rothschild, CEO and Founder, and Eddie Brown, COO of Trifecta Light Technologies, discuss the therapeutic applications of red light and near-infrared therapy by bathing the entire body with these specific light wavelengths. The technology has FDA clearance for fat reduction and healing and clinical research indicates efficacy in neurological disorders and musculoskeletal conditions. The devices are user-friendly and have also been shown to support athletes in recovery and the beauty industry for skin health. Dr. Carl explains, "And so what has since subsequently been learned is that this light of both red, and we also use near infrared, which is even more powerful and more healing; what it does is it affects every cell that we can get to in your body. And the more cells we can get to, the better. That's why you want deep-penetrating, medical-grade beds that can penetrate as much as possible to affect as many cells." Eddie elaborates, "With any kind of red light item, usually the bed, the lights, they're FDA registered, which means basically it's an infrared heat source. What we did with our bed, nobody else was able to do this. Not to say that in the future they're not going to, but right now we're kind of ahead of the curve, the only ones who have it. We've had FDA clearance for ours."   #TrifectaLight #RedLightTherapy #Photobiomodulation #MitochondrialHealth #MetabolicHealth #ChronicCare #SportsMedicine #RegenerativeMedicine Trifectalight.com Listen to the podcast here  

Dr. Carl Rothschild, CEO and Founder, and Eddie Brown, COO of Trifecta Light Technologies, discuss the therapeutic applications of red light and near-infrared therapy by bathing the entire body with these specific light wavelengths. The technology has FDA clearance for fat reduction and healing and clinical research indicates efficacy in neurological disorders and musculoskeletal conditions. The devices are user-friendly and have also been shown to support athletes in recovery and the beauty industry for skin health. Dr. Carl explains, "And so what has since subsequently been learned is that this light of both red, and we also use near infrared, which is even more powerful and more healing; what it does is it affects every cell that we can get to in your body. And the more cells we can get to, the better. That's why you want deep-penetrating, medical-grade beds that can penetrate as much as possible to affect as many cells." Eddie elaborates, "With any kind of red light item, usually the bed, the lights, they're FDA registered, which means basically it's an infrared heat source. What we did with our bed, nobody else was able to do this. Not to say that in the future they're not going to, but right now we're kind of ahead of the curve, the only ones who have it. We've had FDA clearance for ours."  #TrifectaLight #RedLightTherapy #Photobiomodulation #MitochondrialHealth #MetabolicHealth #ChronicCare #SportsMedicine #RegenerativeMedicine Trifectalight.com Download the transcript here